Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebraca Wafer Plus Temozolomide in Recurrent Glioblastoma
NCT07349693Phase 3Not yet recruiting
- Sponsor
- Everfront Biotech Inc.
- Start
- Apr 2027
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of EF-009 in glioblastoma (GBM), sponsored by Everfront Biotech Inc.. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
EF-009
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07349693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349693.